ContributorsPublishersAdvertisers

#Hfpef

ajmc.com

SGLT2 Inhibitors Show Success Against HFpEF in New UK Study

This new investigation into the use of sodium-glucose co-transporter 2 (SGLT2) inhibitors for heart failure shows significant benefit in persons with heart failure with preserved ejection fraction (HFpEF). Using statistical modeling, a new investigation of sodium-glucose co-transporter 2 (SGLT2) inhibitors—the class of medication originally developed for patients with diabetes—from the...
DISEASES & TREATMENTS
Picture for SGLT2 Inhibitors Show Success Against HFpEF in New UK Study
Medscape News

Cardiac Adiposity as a Modulator of Cardiovascular Disease in HIV

Maria Bonou; Chris J. Kapelios; Athanase D. Protogerou; Sophie Mavrogeni; Constantina Aggeli; George Markousis-Mavrogenis; Mina Psichogiou; John Barbetseas. Background: With the number of people living with human immunodeficiency virus (HIV) steadily increasing, cardiovascular disease has emerged as a leading cause of non-HIV related mortality. People living with HIV (PLWH) appear to be at increased risk of coronary artery disease and heart failure (HF), while the underlying mechanism appears to be multifactorial. In the general population, ectopic cardiac adiposity has been highlighted as an important modulator of accelerated coronary artery atherosclerosis, arrhythmogenesis and HF with preserved ejection fraction (HFpEF). Cardiac adiposity is also strongly linked with obesity, especially with visceral adipose tissue accumulation.
Nature.com

The dawn of a new era of targeted therapies for heart failure with preserved ejection fraction (HFpEF)

Although effective treatments exist for heart failure with a reduced ejection fraction (HFrEF), there is a paucity of treatments with proven benefits for heart failure with a preserved ejection fraction (HFpEF). Detailed results from the phase III EMPEROR-Preserved trial were published in The New England Journal of Medicine on August 27, 2021 [1]. The EMPEROR-Preserved trial was a large, international, double-blind and placebo-controlled trial of empagliflozin, a sodium-glucose cotransporter 2 inhibitor (SGLT2-i), in patients with HFpEF (ejection fraction [EF]"‰>"‰40%). In the trial's HFpEF patients, the SGLT2-i empagliflozin led to a 21% lower relative risk (hazard ratio [HR] 0.79, 95% confidence interval [CI]: 0.69"“0.90) of the composite of cardiovascular death or hospitalization for heart failure, which was related mainly to a 29% lower risk (HR 0.73, 95% CI: 0.61"“0.88) of heart failure hospitalization associated with empagliflozin treatment.
Picture for The dawn of a new era of targeted therapies for heart failure with preserved ejection fraction (HFpEF)
TRENDING TOPICS
Medscape News

Sacubitril/Valsartan May Alter Trajectory of Preclinical HFpEF

Sacubitril/valsartan (Entresto) appears to improve measures of cardiac structure and function compared with valsartan alone in asymptomatic preclinical heart failure with preserved ejection fraction, results of the PARABLE trial suggest. The angiotensin receptor-neprilysin inhibitor (ARNI) was also associated with a trend toward fewer serious adverse cardiac events (10.7% vs 19.5%;...
HEALTH
renalandurologynews.com

Empagliflozin: Cardio-Renal Benefits in HF, LVEF Above 40% Regardless of CKD Status

Treatment with empagliflozin reduced the risk of cardiovascular death or hospitalization for heart failure and slowed kidney function decline in adults with heart failure and left ventricular ejection fraction (LVEF) over 40% regardless of chronic kidney disease (CKD) status, according to new prespecified sub-analysis of the phase 3 EMPEROR-Preserved trial.
Newswise

Factors Associated With Cognitive Impairment in Heart Failure With Preserved Ejection Fraction

Cognitive impairment is prevalent in heart failure and is associated with higher mortality rates. The mechanism behind cognitive impairment in heart failure with preserved ejection fraction (HFpEF) has not been established. Objective. The aim of this study was to evaluate associations between abnormal cardiac hemodynamics and cognitive impairment in individuals...
ajmc.com

Sacubitril/Valsartan Treatment for HFpEF Shown to Reduce NT-proBNP Levels

Wanting more data on the benefits of sacubitril/valsartan vs renin angiotensin system inhibitor background therapy, investigators conducted a large randomized study among persons with heart failure with preserved ejection fraction (HFpEF). Among several measures evaluated in a 24-week, randomized, double-blind, parallel group clinical trial comparing outcomes among patients with heart...
HEALTH
networthynewz.com

EMPEROR-Preserved Findings Confirmed in ‘True’ HFpEF Patients

Main results from the landmark EMPEROR-Preserved trial, reported in August, established for the first time that treatment with a drug, the sodium-glucose cotransporter 2 inhibitor empagliflozin, could clearly benefit patients with heart failure with preserved ejection fraction (HFpEF). The only caveat was that EMPEROR-Preserved enrolled patients with a left ventricular...
DISEASES & TREATMENTS
physiciansweekly.com

HFpEF: ARNI Reduced NT-proBNP But Did Not Increase Exercise Capacity

The angiotensin receptor-neprilysin inhibitor (ARNI) sacubitril/valsartan brought significantly decreased plasma N-terminal pro-brain natriuretic peptide (NT-proBNP) levels compared with both standard renin angiotensin system (RAS) inhibitor treatment and placebo in heart failure patients with preserved ejection fraction (HFpEF; >40%), according to results from the PARALLAX study. Sacubitril/valsartan did not, however, significantly improve 6-minute walk distance or quality of life.
FITNESS
tctmd.com

Empagliflozin Retains Benefits in ‘True’ HFpEF Patients

Empagliflozin (Jardiance; Boehringer Ingelheim/Eli Lilly) provides a wide range of benefits in patients with “true” heart failure and preserved ejection fraction (HFpEF) , meaning an LVEF of 50% or greater, EMPEROR-Preserved investigators report. The main results of the placebo-controlled trial, released over the summer, showed that the sodium-glucose cotransporter 2...
SCIENCE
mdedge.com

EMPEROR-Preserved findings confirmed in ‘true’ HFpEF patients

Main results from the landmark EMPEROR-Preserved trial, reported in August, established for the first time that treatment with a drug, the sodium-glucose cotransporter 2 inhibitor empagliflozin, could clearly benefit patients with heart failure with preserved ejection fraction (HFpEF). The only caveat was that EMPEROR-Preserved enrolled patients with a left ventricular...
DISEASES & TREATMENTS
mdedge.com

Advanced CKD doesn’t derail empagliflozin in EMPEROR-preserved

Chronic kidney disease (CKD) had no impact on the efficacy or safety of the sodium-glucose cotransporter 2 (SGLT2) inhibitor empagliflozin (Jardiance, Boehringer Ingelheim) for patients with heart failure with preserved ejection fraction (HFpEF) in the EMPEROR-Preserved trial, showing once again that agents in this class are appropriate for patients with heart failure even when their kidney function is severely compromised.
DISEASES & TREATMENTS
MedPage Today

Peak VO2 Improved After Beta-Blocker Withdrawal in Some HFpEF Patients

Short-term withdrawal of beta-blockers improved exercise outcomes in certain patients with heart failure with preserved ejection fraction (HFpEF), according to a small randomized trial. After 2 weeks of beta-blocker withdrawal, patients with stable HFpEF and chronotropic incompetence showed a significant increase in peak oxygen consumption (VO2) during exercise (14.3 vs...
DISEASES & TREATMENTS
masterdoctor.net

Empagliflozin beneficial in ‘true' HFpEF with higher ejection fraction

In a new analysis of the EMPEROR-Preserved trial, the SGLT2 inhibitor empagliflozin reduced CV death or HF hospitalization by 17% among those with a left ventricular ejection fraction of at least 50%. “This trial shows that for patients with a 50% of higher EF - what the guidelines consider the...
SCIENCE
pharmacytimes.com

Empagliflozin Improved Outcomes for Patients With Heart Failure, Chronic Kidney Disease

Empagliflozin reduced the risk of cardiovascular death or hospitalization for heart failure and slowed kidney function decline in adults with heart failure with left ventricular ejection fraction (LVEF) over 40% regardless of chronic kidney disease (CKD) status at baseline, according to the results of a prespecified sub-analysis of the EMPEROR-Preserved phase 3 trial. The results were presented at the American Society of Nephrology Kidney Week 2021.
DISEASES & TREATMENTS
themedicalprogress.com

Advanced CKD Doesn't Derail Empagliflozin in EMPEROR-Preserved

Chronic kidney disease (CKD) had no impact on the efficacy or safety of the sodium-glucose cotransporter 2 (SGLT2) inhibitor empagliflozin (Jardiance, Boehringer Ingelheim) for patients with heart failure with preserved ejection fraction (HFpEF) in the EMPEROR-Preserved trial, showing once again that agents in this class are appropriate for patients with heart failure even when their kidney function is severely compromised.
DISEASES & TREATMENTS
YOU MAY ALSO LIKE